Lyra Therapeutics Announces $29.5 Million Series B Financing to Advance Innovative Therapeutics for Ear, Nose and Throat Diseases Company’s lead product candidate, LYR-210, to enter Phase 2 clinical study for chronic rhinosinusitis

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2Q82evJ
via IFTTT